174 related articles for article (PubMed ID: 34996489)
21. Uncommon somatic mutations in metastatic NUT midline carcinoma.
Cavalieri S; Stathis A; Fabbri A; Sonzogni A; Perrone F; Tamborini E; Pelosi G; de Braud F; Platania M
Tumori; 2017 Nov; 103(Suppl. 1):e5-e8. PubMed ID: 28967088
[TBL] [Abstract][Full Text] [Related]
22. NUT midline carcinoma in a newborn with multiorgan disseminated tumor and a 2-year-old with a pancreatic/hepatic primary.
Shehata BM; Steelman CK; Abramowsky CR; Olson TA; French CA; Saxe DF; Ricketts RR; Katzenstein HM
Pediatr Dev Pathol; 2010; 13(6):481-5. PubMed ID: 20017639
[TBL] [Abstract][Full Text] [Related]
23. Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report.
Sun L; Yang M; Zhang X; Li H; Wu L; Zhang Y; Cai S
Medicine (Baltimore); 2020 May; 99(20):e20053. PubMed ID: 32443311
[TBL] [Abstract][Full Text] [Related]
24. [A Case Report of Advanced Lung Adenocarcinoma Harboring KRAS Mutation
Treated with Anlotinib].
Su Y; Meng Z; Xu X; Wang X; Zuo R; Hou Y; Li K; Chen P
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):428-430. PubMed ID: 29764596
[TBL] [Abstract][Full Text] [Related]
25. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
Long ZY; Lu Y; Li M; Chen G; Shi L; Xiao X; Bai Y; Zhang HM; Wang Z
Ann Palliat Med; 2021 Jun; 10(6):7073-7082. PubMed ID: 33548989
[TBL] [Abstract][Full Text] [Related]
26. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
27. Anlotinib is effective in the treatment of advanced pancreatic cancer: a case report.
Li S; Niu M; Deng W; Li N; Wei C; Luo S
Anticancer Drugs; 2022 Jan; 33(1):e558-e561. PubMed ID: 34387586
[TBL] [Abstract][Full Text] [Related]
28. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
29. Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.
Tang M; Song C; Zhang Y; Xu X; Wang C; Zhang Z; Chen T
Lipids Health Dis; 2021 Nov; 20(1):165. PubMed ID: 34801029
[TBL] [Abstract][Full Text] [Related]
30. NUT midline carcinoma of the parotid gland with mesenchymal differentiation.
den Bakker MA; Beverloo BH; van den Heuvel-Eibrink MM; Meeuwis CA; Tan LM; Johnson LA; French CA; van Leenders GJ
Am J Surg Pathol; 2009 Aug; 33(8):1253-8. PubMed ID: 19561446
[TBL] [Abstract][Full Text] [Related]
31. NUT Midline Carcinoma of the Lung in a Six-Year-Old Child.
Karakuş E; Poyraz A; Oğuz Erdogan AS; Emir S; Özyörük D
Fetal Pediatr Pathol; 2017 Dec; 36(6):472-474. PubMed ID: 29220605
[TBL] [Abstract][Full Text] [Related]
32. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
[TBL] [Abstract][Full Text] [Related]
33. NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue.
Suzuki S; Kurabe N; Ohnishi I; Yasuda K; Aoshima Y; Naito M; Tanioka F; Sugimura H
Pathol Res Pract; 2015 May; 211(5):404-8. PubMed ID: 25466466
[TBL] [Abstract][Full Text] [Related]
34. First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.
Vulsteke C; Lurquin E; Debiec-Rychter M; Gheysens O; Nuyts S; Schoenaers J; Politis C; Mebis J; Hauben E; Clement PM
J Chemother; 2016 Jun; 28(3):242-6. PubMed ID: 26027633
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological and molecular characterizations of pulmonary NUT midline carcinoma.
Xie M; Fu X; Wang W
Cancer Med; 2021 Sep; 10(17):5757-5764. PubMed ID: 34409758
[TBL] [Abstract][Full Text] [Related]
36. Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations.
Sholl LM; Nishino M; Pokharel S; Mino-Kenudson M; French CA; Janne PA; Lathan C
J Thorac Oncol; 2015 Jun; 10(6):951-9. PubMed ID: 26001144
[TBL] [Abstract][Full Text] [Related]
37. Primary pulmonary nuclear protein of the testis midline carcinoma: case report and systematic review with pooled analysis.
Zhao D; Cao W; Zha S; Wang Y; Pan Z; Zhang J; Hu K
Front Oncol; 2023; 13():1308432. PubMed ID: 38264746
[TBL] [Abstract][Full Text] [Related]
38. Bronchial Fistula: Rare Complication of Treatment with Anlotinib.
Deng P; Hu C; Li Y; Cao L; Yang H; Li M; An J; Jiang J; Gu Q
Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):858-865. PubMed ID: 32987493
[TBL] [Abstract][Full Text] [Related]
39. Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review.
Zuo R; Zhang C; Lin L; Meng Z; Wang Y; Su Y; Abudurazik M; Du Y; Chen P
Thorac Cancer; 2020 Nov; 11(11):3383-3387. PubMed ID: 32997432
[TBL] [Abstract][Full Text] [Related]
40. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
Yu G; Cai Q; Xu X; Shen Y; Xu K
PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
